Making it in Manufacturing

Making it in Manufacturing

Download on the App Store

Making it in Manufacturing episodes

  • CPHI Milan 2026: Molecule First, Patient Always - Chris Davison

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto

    Centrix Pharma Solutions helps biotech companies move from preclinical development into early stage clinical development. For CEO Chris Davison, that means the molecule first and the patient always: "we don't just make a product, we make medicines."

    This week on Making It In Manufacturing, Harry Sloan sat down with Chris Davison, CEO of Centrix Pharma Solutions, a small CDMO based in the UK, at CPHI Milan 2026, where ARTO was the official podcast partner.

    In this episode, Chris covers:

    (00:57) What Centrix does: formulation, analytical work and clinical manufacturing for biotech companies heading into the clinic, and what "Molecule First, Patient Always" means in practice.

    (02:23) His path to CEO: a pharmacist by training, 23 years at GSK in pharmaceutical development and leading CMC teams, then manufacturing supply chain and launches, before moving to Custom Pharmaceuticals and stepping up to lead the business.

    (04:03) Going from big pharma to a small company: wearing multiple hats, relying on your network, and not being afraid to ask for help.

    (05:16) Why now was the time to launch Centrix out of Custom Pharmaceuticals, a business that has been around for 47 years, and why it helps clients with what they need today and what they will need tomorrow.

    (07:23) Partnership, not transactions: challenging small biotechs on the consequences of their decisions down the line, so they make them with their eyes wide open.

    (09:41) The Integrated CMC Partnership with Sai Life Sciences and Agility Life Sciences, built to take the handoff out between drug substance and drug product.

    (12:28) Backing the growth plans: equipment that gives very rich data from small amounts of material, and an Innovate UK knowledge transfer partnership with the University of Sussex that brings a data scientist into the business.

    (15:05) What growth depends on: clients, the funding bar for biotech, and talent, with recent recruits from Brighton University, and why the people in a business drive its credibility.

    (18:12) How biotechs now choose a development partner: shorter runways, more selective, and wanting help to navigate their own journey rather than just a formulation and a batch.

    (19:09) Where AI fits at Centrix today: models to inform drug development, help in the quality functions with the human still at the centre, and empowering the workforce rather than replacing it.

    (21:40) What he wants Centrix to have delivered a year from now.

    Watch the full episode to hear why Chris wants more people to know what it really takes to develop a product.

    Follow ARTO

    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent

    Chris Davison

    LinkedIn: https://www.linkedin.com/in/chrisdavison155/

    Harry Sloan

    LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

    Timestamps:

    00:00 Introduction

    00:57 What Centrix does

    02:23 From pharmacist to CEO

    04:03 Big pharma to a small company

    05:16 Why launch Centrix now

    07:23 Partnership, not transactions

    09:41 The Integrated CMC Partnership

    12:28 Investing in data and growth

    15:05 What growth depends on

    18:12 How biotechs choose a partner

    19:09 Where AI fits today

    21:40 A year from now

    #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #CDMO #Biotech #CMC #DrugDevelopment

    Hosted on Acast. See acast.com/privacy for more information.

    24 min
  • CPHI Milan 2026: Capacity Is Not The Issue Anymore, It's Certainty - Katie Edgar and Sigma Mostafa

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto

    Five years ago, everybody was focused on capacity. For Katie Edgar and Sigma Mostafa of KBI Biopharma, capacity is not the issue anymore: what customers need is certainty, and it starts with planning for the problems before they happen.

    This week on Making It In Manufacturing, Elliot Payne sat down with Katie Edgar, Chief Business Officer, and Sigma Mostafa, Chief Scientific & Technology Officer at KBI Biopharma, at CPHI Milan 2026, where ARTO was the official podcast partner.

    In this episode, Katie and Sigma cover:

    (00:29) What KBI Biopharma does: an end-to-end CDMO in mammalian and microbial, from pre-clinical to commercial manufacturing, with four commercial products and 50 plus early stage molecules a year.

    (01:22) Katie's journey from strategy and law to leading business development as Chief Business Officer.

    (03:45) Why Katie calls herself a paid pessimist, and how setting expectations early gives customers certainty.

    (05:32) How the two work together, and their advice for anyone stepping into a C-suite role, especially women.

    (07:16) Sigma's journey at KBI, from building process development from the ground up to leading about 500 people.

    (09:09) Failing fast, learning fast, and taking accountability as a leader.

    (12:21) Whether it's getting better for women in the industry, and why a strategy to come back after time off matters.

    (13:25) What makes KBI a technical powerhouse but nimble, in its 30th anniversary year.

    (17:28) Scientific depth with commercial sense, and why the quality of the data is the differentiator.

    (21:10) Celebrating the wins, and KBI's monthly win room.

    (23:48) The one thing they would remove from pharma manufacturing.

    Watch the full episode to hear why Katie believes the market now wants certainty, not capacity.

    Follow ARTO

    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent

    Katie Edgar

    LinkedIn: [Katie Edgar LinkedIn]

    Sigma Mostafa

    LinkedIn: [Sigma Mostafa LinkedIn]

    Elliot Payne

    LinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/

    Timestamps:

    00:00 Introduction

    00:29 What KBI Biopharma does

    01:22 Katie's journey

    03:45 The paid pessimist

    05:32 Stepping into the C-suite

    07:16 Growing with KBI

    09:09 Failing fast and accountability

    12:21 Women in the industry

    13:25 Technical powerhouse, but nimble

    17:28 Science, business and data

    21:10 Celebrating the wins

    23:48 One thing to remove from the industry

    #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #CDMO #Biologics #WomenInLeadership #Leadership

    Hosted on Acast. See acast.com/privacy for more information.

    29 min
  • CPHI Milan 2026: Can The Asset Deliver The Value? - Sven Remmerbach

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto

    When a private equity firm looks at a pharma manufacturing site, the financial analysis can tell it what happened. Sven Remmerbach, Managing Director of pharmBridge, answers the simpler question: can the asset deliver the value the investor is looking for?

    This week on Making It In Manufacturing, Elliot Payne sat down with Sven Remmerbach, Managing Director of pharmBridge, who ran two manufacturing sites at Baxter before moving into consulting, at CPHI Milan 2026, where ARTO was the official podcast partner.

    In this episode, Sven covers:

    (00:58) His path from pharmacy studies and a PhD, through internships in hospital and local pharmacies and in industry, into pharmaceutical manufacturing.

    (02:16) What pharmBridge offers: senior leaders and project experts who help pharma companies execute transformations, technology transfers and strategic investments.

    (02:45) Why he stayed at Baxter so long: learning in its contract manufacturing business, P&L responsibility, and a mission of serving patients.

    (04:13) His most rewarding period: the early days of contract manufacturing, on the front line with clients.

    (05:33) Advice for anyone stepping up to run large teams across sites: shared values, shared goals, smart KPIs and daily disciplines.

    (06:45) Whether leadership came naturally, and how he learned it from small teams upwards.

    (07:53) Moving from running sites to consulting, where nobody books your flights any more.

    (09:00) What pharmBridge does when a PE firm brings it in to look at a pharma manufacturing asset.

    (10:01) The one question PE firms should ask themselves before acquiring a site.

    (11:31) Whether he's enjoying it: faster decision cycles, and the freedom to just do things.

    (12:00) The one thing he would take out of pharma manufacturing.

    Watch the full episode to hear why Sven believes the organisation can matter more than the equipment.

    Follow ARTO

    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent

    Sven Remmerbach

    LinkedIn: [Sven Remmerbach LinkedIn]

    Elliot Payne

    LinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/

    Timestamps:

    00:00 Introduction

    00:58 From pharmacy to manufacturing

    02:16 What pharmBridge offers

    02:45 Why he stayed at Baxter

    04:13 His most rewarding role

    05:33 Leading large teams across sites

    06:45 Learning to lead

    07:53 From site leader to consultant

    09:00 Working with PE firms

    10:01 One question for PE buyers

    11:31 Enjoying the freedom

    12:00 One thing to remove from the industry

    #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #PrivateEquity #Leadership #PharmaManufacturing #TechTransfer

    Hosted on Acast. See acast.com/privacy for more information.

    14 min
  • CPHI Milan 2026: Getting Trial Medicines From A To B - Catherine Parry and Jamie Beaumont

    COREX has spent 15 years moving clinical trial supplies and medicines across the globe. It doesn't manufacture anything. Its job is to make sure what sponsors make gets from A to B, and that the medicines they need are sourced, relabelled and delivered from B to C.


    This week on Making It In Manufacturing, Ruby Collier sat down with Jamie Beaumont, Global Head of Clinical Trial Sourcing, and Catherine Parry, Business Development Director at COREX, at CPHI Milan 2026, where ARTO was the official podcast partner.


    In this episode, Jamie and Catherine cover:


    (01:05) What COREX does: clinical trial logistics, named patient programmes, and sourcing the commercial medicines sponsors and CROs need for their studies.


    (02:21) Where COREX sits in the supply chain, alongside CROs, CDMOs, biotechs and sponsors.


    (03:01) Why they both joined COREX this year: its reputation for customer service, and the push into international and emerging markets.


    (05:08) What happens when a sponsor needs a comparator, from central sourcing in bulk to buying in a single country for a single patient.


    (06:26) When sponsors realise they have a supply problem (probably too late), and why the conversation should start earlier.


    (07:49) What's driving COREX's growth after 15 years: more services, in more countries.


    (08:58) How COREX competes with the giant logistics players: reliability, supply chain security, knowledge and the personal touch.


    (10:33) The next three to five years: busier trials, more flexible supply, less wastage, and more focus on recruiting and keeping patients.


    (13:32) One piece of advice for a sponsor starting a global trial tomorrow.


    Listen to the full episode to hear why, for COREX, there's always a patient at the end of the service.


    Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent


    Catherine Parry

    LinkedIn: https://www.linkedin.com/in/catherine-parry-55107a4b/


    Jamie Beaumont

    LinkedIn: https://www.linkedin.com/in/jamie-beaumont-2b63b9250/


    Ruby Collier

    LinkedIn: https://www.linkedin.com/in/rubycollier/


    Timestamps:


    00:00 Introduction

    01:05 What COREX does

    02:21 Where COREX sits in the supply chain

    03:01 Why they joined COREX

    05:08 Inside comparator sourcing

    06:26 Why sponsors call too late

    07:49 What's driving the growth

    08:58 Competing with the giants

    10:33 The next three to five years

    13:32 One piece of advice


    #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #ClinicalTrials #ClinicalSupply #ComparatorSourcing #PharmaLogistics

    Hosted on Acast. See acast.com/privacy for more information.

    15 min
  • CPHI Milan 2026: The Biosimilar Boom Has Flipped Supply And Demand - Himanshu Gadgil

    This week on Making It In Manufacturing, Elliot Payne sat down again with Himanshu Gadgil, Ph.D., CEO of Enzene, at CPHI Milan 2026, where ARTO was the official podcast partner.


    In this episode, Himanshu covers:


    (00:54) Enzene's last 12 months: the Manufacturing Excellence Award, its New Jersey facility fully running with two suites, and a full technology transfer offer for anyone who wants to onshore manufacturing.


    (02:12) Why Enzene is opening up its continuous manufacturing platform: to reach the tipping point where a lot more people adopt it.


    (02:59) The biosimilar boom seen at CPHI this year, and why the supply and demand equation has flipped.


    (04:30) How Enzene stands out: a platform built for India's price-sensitive market, so it was cost effective from the start.


    (05:58) What comes next for EnzeneX®: from 200 litres to 1,000 litres in 2.0, then process analytics, its own media, and AI that makes process decisions dynamically.


    (07:23) Intuition or data: how he makes decisions, and how AI gives the team very quick access to what the data is saying.


    (08:59) The decisions that shaped Enzene: becoming a full CDMO, and moving into pet health, where it works with four of the top five pet health companies.


    (10:13) The one process he would remove from pharma manufacturing.


    Watch the full episode to hear why Himanshu believes the best cost of goods will win as so many biologics come off patent.


    Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/


    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw


    Instagram: https://www.instagram.com/arto.talent


    TikTok: https://www.tiktok.com/@artotalent


    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245


    Website: https://arto-talent.com/


    Youtube: https://www.youtube.com/@artotalent


    Himanshu Gadgil


    LinkedIn: https://www.linkedin.com/in/himanshu-gadgil-3326307/


    Elliot Payne


    LinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/


    Timestamps:


    00:00 Introduction


    00:54 Enzene's last 12 months


    02:12 Opening up continuous manufacturing


    02:59 The biosimilar boom


    04:30 Winning on cost of goods


    05:58 EnzeneX® 3.0 and beyond


    07:23 Intuition, data and AI


    08:59 Decisions that shaped Enzene


    10:13 One thing to remove from the industry


    #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #Biosimilars #ContinuousManufacturing #Biologics #CDMO

    Hosted on Acast. See acast.com/privacy for more information.

    12 min
  • CPHI Milan 2026: The White Drums With The Red Lid - Bart van Berkel

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    Many in the pharma industry know CurTec for its white drums with the red lid, used to handle, store and contain the ingredients that go into medicines. CEO Bart van Berkel explains why pharma is the only industry CurTec focuses on.


    This week on Making It In Manufacturing, Harry Sloan sat down with Bart van Berkel, CEO of CurTec, at CPHI Milan 2026, where ARTO was the official podcast partner.


    In this episode, Bart covers:


    (01:00) What CurTec does: packaging that helps pharmaceutical companies, API and excipient suppliers and CMOs handle, store and contain the ingredients used to make medicines.


    (01:32) What carried over from aerospace: a highly regulated industry, long customer relationships, high standards of quality, and approval processes that take long for a good reason.


    (02:59) What makes a drum or pail pharmaceutical grade: easy to operate in suits and gloves, screw lids, GMP at the core, and designs that can dock to isolators.


    (04:16) Sustainability: taking material out, packaging that can be reused, and a redesigned drum with no handles or rubber gasket and a 30% CO2 reduction against CurTec's own products.


    (05:27) Why CurTec, opened in the 1950s in the Netherlands, built a factory in South Carolina and moved all its American customers to it.


    (07:35) Building greenfield to embed the CurTec culture of safety, compliance and cleanliness from the start, with a team of 30 and growing.


    (08:52) How pharma supply chains are shifting, and CurTec's commercial team in Asia working with suppliers of APIs and excipients.


    (10:01) Where CurTec could be in five years: very likely a facility in Asia, and new products that take it closer to pharma operations.


    (10:49) What he wants people to remember: CurTec is super dedicated to the pharma industry.


    Watch the full episode to hear why Bart wants anyone with a packaging problem to give CurTec a call.


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent


    Bart van Berkel

    LinkedIn: https://www.linkedin.com/in/bart-van-berkel-3824b3/


    Harry Sloan

    LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/


    Timestamps:

    00:00 Introduction

    01:00 What CurTec does

    01:32 From aerospace to pharma

    02:59 What makes packaging pharma grade

    04:16 Sustainability and lighter drums

    05:27 Why South Carolina

    07:35 Building the CurTec culture

    08:52 How pharma supply chains are changing

    10:01 CurTec in five years

    10:49 What to remember about CurTec


    #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #PharmaPackaging #Sustainability #GMP #PharmaSupplyChain

    Hosted on Acast. See acast.com/privacy for more information.

    13 min
  • CPHI Milan 2026 Newsbeat: The Digital CMC Consortium Launches To Digitise CMC - Luke Guerrero

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    On the first day of CPHI Milan 2026, the Digital CMC Consortium launched: a pre-competitive, not-for-profit collaboration across the industry to digitise end-to-end CMC, founded with participation from companies including Novartis, Takeda and Thermo Fisher.


    On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Luke Guerrero, one of the founding members and now Director of Operations of the Digital CMC Consortium, about the launch and what comes next.


    In this episode, Luke covers:


    (00:26) The launch: why biotechs, sponsors, CDMOs and consultancies have come together to solve the problems that can only be solved together.


    (01:18) Why sponsor to CDMO technology transfer is the first use case, and what a frictionless transfer would look like: as easy as moving to a new phone, instead of typing in every contact by hand.


    (02:55) How the consortium will turn standards into day-to-day practice: starting from the real workflow between sponsor and CDMO, building in pieces and iterating with members, and working with existing standards rather than replacing them.


    (04:27) What the consortium wants from the CPHI community: the varied perspectives of sponsors, CDMOs and equipment makers across the whole CMC value chain.


    Watch the full episode to hear how the Digital CMC Consortium plans to make tech transfer easier, so teams can focus on the real science.


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent


    Luke Guerrero

    LinkedIn: https://www.linkedin.com/in/lukeguerrero/


    Ruby Collier

    LinkedIn: https://www.linkedin.com/in/ruby-collier/


    Timestamps:

    00:00 Introduction

    00:22 The launch of the Digital CMC Consortium

    01:06 Why tech transfer is the first use case

    02:46 Turning shared standards into everyday practice

    04:18 What the consortium wants from the CPHI community

    05:05 Closing thoughts


    #Newsbeat #ARTOTalent #CPHI #CPHIMilan #CMC #TechTransfer #DigitalTransformation #CDMO #Pharma

    Hosted on Acast. See acast.com/privacy for more information.

    6 min
  • CPHI Milan 2026 Newsbeat: Quotient Sciences Takes AI Into A Clinical Trial - Andy Lewis

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    Quotient Sciences has announced interim results from its AI-driven clinical trial. After three years developing AI for formulation development, with 30 to 50% time savings, Quotient took the approach into the clinic to see if it could also learn how a formulation's composition relates to its performance in people.


    On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Andy Lewis, Chief Scientific Officer of Quotient Sciences, about the results and what they could mean for drug development.


    In this episode, Andy covers:


    (00:25) The interim results: the AI appears to have learned the link between composition and in vivo performance after testing just three prototypes, which could reduce the clinical testing a product needs.


    (01:25) How the algorithm learned: active learning with Bayesian optimisation, starting untrained, trained first on in vitro data and then on the emerging clinical data, with a safety committee reviewing every formulation it requested. When the team changed the target to rule out luck, it hit that one too.


    (03:27) What it could mean for modified release products: fewer formulation screens, faster clinical development, and an in silico model of the drug product, like a digital twin, that could support scale-up and post-approval changes such as a change of site.


    (05:05) What drug developers at CPHI Milan are most excited about: a first look at the pharmacokinetic data, and how the tool's visualisations map onto quality by design.


    Watch the full episode to hear how Quotient Sciences is using AI to save time at every step of drug product development.


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent


    Andy Lewis

    LinkedIn: https://www.linkedin.com/in/andylewis1/


    Ruby Collier

    LinkedIn: https://www.linkedin.com/in/ruby-collier/


    Timestamps:

    00:00 Introduction

    00:16 Quotient's interim clinical trial results

    01:25 How the algorithm learned from each dosing period

    03:27 What it could mean for modified release development

    05:05 What drug developers at CPHI are excited about

    06:08 Closing thoughts


    #Newsbeat #ARTOTalent #CPHI #CPHIMilan #AI #MachineLearning #FormulationDevelopment #DrugDevelopment #ClinicalTrials

    Hosted on Acast. See acast.com/privacy for more information.

    7 min
  • CPHI Milan 2026: From 500 Million To A Billion Units - Ankit Gupta

    95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes.


    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    A year ago, InstaPill was adding a new block to take its capacity in India to 500 million units. Now CEO Ankit Gupta plans a new greenfield site to double that to a billion, able to handle everything that is ODT.


    This week on Making It In Manufacturing, Harry Sloan caught up again with Ankit Gupta, CEO of InstaPill, at CPHI Milan 2026, where ARTO was the official podcast partner.


    In this episode, Ankit covers:


    (01:12) Why InstaPill is planning a new greenfield site in India, on about 18 acres of land, modular so capacity can grow with demand.

    (02:35) The move to a CDMO and B2B model, built on its two strengths: development and manufacturing.

    (03:55) What sets InstaPill apart: transparency and flexibility, with projects partners typically do in 9 to 10 months delivered in 3 to 6.

    (05:01) Where a US site fits: the bulk of its partners are in the US, and the plan stays on track for when partners need it.

    (06:22) What to ask him about next year: more visible partnerships and more products reaching the market.


    Watch the full episode to hear why Ankit wants partners to think of InstaPill as the company that can do everything that is possible on ODT.


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/

    Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw

    Instagram: https://www.instagram.com/arto.talent

    TikTok: https://www.tiktok.com/@artotalent

    Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent


    Ankit Gupta

    LinkedIn: https://www.linkedin.com/in/reachankit/


    Harry Sloan

    LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/


    Timestamps:

    00:00 Introduction

    01:12 Doubling to a billion units

    02:35 From own products to CDMO partner

    03:55 Transparency and flexibility

    05:01 The plan for the US

    06:22 What to watch for next year


    #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #ODT #CDMO #DrugDelivery #PharmaManufacturing

    Hosted on Acast. See acast.com/privacy for more information.

    8 min
  • CPHI Milan 2026: Taking Manufacturing Out Of The Dark Ages - Sheena Dempsey

    Drug discovery and clinical development have all benefited from the COVID era and the AI era, but for Sheena Dempsey, manufacturing is still stuck somewhat in the dark ages. As President and CEO of CAI, she wants to drive automation and acceleration that get medicines into the hands of patients faster.


    This week on Making It In Manufacturing, Elliot Payne sat down with Sheena Dempsey, President and CEO of CAI, the global consultancy for commissioning and qualification and operational readiness, at CPHI Milan 2026, where ARTO was the official podcast partner.


    In this episode, Sheena covers:


    (00:57) What CAI does: commissioning and qualification, operational readiness and operational excellence for most of the top pharmaceutical companies, with about 750 people across North America, Europe and APAC.


    (02:06) The new partnership with JLL Partners, and her three to five year plan to grow CAI, organically and inorganically, in footprint and in services.


    (03:13) What drew her to CAI after building life sciences practices in professional services, and why she calls herself a global misfit.


    (04:44) Getting experienced people and Gen Z and Gen Alpha digital natives working well together: the goals are the same, and it takes leadership, change management and training on both sides.


    (06:58) Why paper in manufacturing plants is unacceptable today, and why digitisation lends itself to compliance and stops knowledge being lost.


    (07:43) What CAI looks for in new people, and managing talent as a portfolio, from trade schools and internships to graduates.


    (10:03) Why CAI is building its own trade school pipeline for aseptic manufacturing, where the demand for talent is enormous.


    (12:06) What success in 2027 looks like: the right balance of skills, global teams built around a customer's need, and the excitement of a plant's first batch.


    (13:31) The one thing she would remove from pharma manufacturing: its deeply held resistance to change.


    (14:23) Why she is optimistic: pockets of real innovation at particular sites, led by site heads and change agents.


    Watch the full episode to hear why Sheena believes the inflection point manufacturing needs is already in play.


    Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


    Follow ARTO


    LinkedIn: https://www.linkedin.com/company/artotalent/


    Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng


    Instagram: https://www.instagram.com/arto.talent


    TikTok: https://www.tiktok.com/@artotalent


    Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575


    Website: https://arto-talent.com/


    Youtube: https://www.youtube.com/@artotalent


    Sheena Dempsey


    LinkedIn: https://www.linkedin.com/in/sheena-dempsey-b693575/


    Elliot Payne


    LinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/


    Timestamps:


    00:00 Introduction


    00:57 What CAI does


    02:06 The JLL Partners partnership


    03:13 Why Sheena chose CAI


    04:44 Bringing generations together


    06:58 Taking paper out of manufacturing


    07:43 What CAI looks for in talent


    10:03 Building a trade school pipeline


    12:06 What success looks like in 2027


    13:31 One thing to remove from the industry


    14:23 Reasons for optimism


    #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #Commissioning #Qualification #Digitalisation #PharmaManufacturing

    Hosted on Acast. See acast.com/privacy for more information.

    17 min

About Making it in Manufacturing

From the publisher's feed

97% of our listeners don't realise they aren't followed, please double check, thank you!


Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series,…